TELA Bio, Inc. (TELA): Submission of Matters to a Vote of Security Holders
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 8, 2026, TELA Bio, Inc. (the “ Company ”) held a Special Meeting of Stockholders (the “ Special Meeting ”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstandin
How this was made
The 30-second read
Why it matters
Regaining compliance eliminates a near‑term regulatory risk, which could stabilize or modestly lift the stock.
Market read
The filing removes a delisting threat, a material corporate action for a micro‑cap biotech.
What to watch
Potential future dilution if a reverse split is later re‑considered.
Background
TELA Bio is a clinical‑stage biotech listed on Nasdaq. The company previously faced a potential delisting due to low share price.
Ticker impact
TELA Bio disclosed it regained Nasdaq minimum bid price compliance and cancelled a planned reverse stock split after a special shareholder meeting.
modest upside as market prices in compliance restoration
The filing is the first public notice of compliance; investors typically view removal of a delisting threat favorably.
Market effects
None significant; compliance news is company‑specific.
No broader regional effect.
Limited to investors in the biotech micro‑cap space.
Counterpoint
The compliance news may be already priced in; share price could remain flat.
Key entities
- personHeather Getz
CEO and Director of TELA Bio, signatory of the 8‑K filing.
